Treatment-Indication Bias: Patients with more extensive carotid disease were more likely to receive lipid-lowering therapy (13.9% with CP vs 8.1% without), suggesting that intensive treatment was more likely to have been administered to higher-risk patients, potentially creating inverse associations between lipid levels and stroke risk. This evidence concerns the gene CP and Stroke.